Advanced NanoTherapies

Advanced NanoTherapies develops drug delivery devices for cardiac vascular diseases, offering the SirPlux Duo Drug-Coated Balloon based on proprietary nanoparticle technology for sustained drug release to treat coronary artery disease. The device delivers therapeutic agents directly to arterial walls during angioplasty procedures, utilizing nanoparticle formulations to optimize drug retention and therapeutic efficacy. Founded in 2018 and headquartered in Los Gatos, United States, Advanced NanoTherapies has raised approximately $57.4M in Series B funding from investors including Cleveland Clinic, ForMED Ventures, S3 Ventures, and T45 Labs. The company employs 19 people and focuses on addressing the limitations of conventional drug-coated balloons by using nanotechnology to enhance drug delivery precision and duration, potentially reducing restenosis rates and improving outcomes for patients undergoing coronary interventions.